Alternative Data for Bio-Rad
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 167 | Sign up | Sign up | Sign up |
| Sentiment | N/A | Sign up | Sign up | Sign up |
| Webpage traffic | 549,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 15 | Sign up | Sign up | Sign up |
| Facebook Followers | 13,653 | Sign up | Sign up | Sign up |
| Instagram Followers | 17,388 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,001 | Sign up | Sign up | Sign up |
| X Followers | 16,006 | Sign up | Sign up | Sign up |
| X Mentions | 56 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 39 | Sign up | Sign up | Sign up |
| Linkedin Employees | 9,268 | Sign up | Sign up | Sign up |
About Bio-Rad
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market.
| Price | $262.80 |
| Target Price | Sign up |
| Volume | 314,932 |
| Market Cap | $7.09B |
| Year Range | $241.95 - $339.75 |
| Dividend Yield | 0% |
| PE Ratio | 9.43 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm LeadingFebruary 22 - Yahoo |
|
International Markets and Bio-Rad (BIO): A Deep Dive for InvestorsFebruary 19 - Yahoo |
|
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow GrowthFebruary 19 - Yahoo |
|
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock DownFebruary 18 - Yahoo |
|
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price WeaknessFebruary 15 - Yahoo |
|
Assessing Bio-Rad Laboratories (BIO) Valuation After Prolonged Share Price WeaknessFebruary 15 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 653M | 310M | 343M | -342M | -385M | 2.260 |
| Q2 '25 | 652M | 306M | 345M | 318M | 477M | 2.610 |
| Q1 '25 | 585M | 279M | 306M | 64M | 134M | 2.540 |
| Q4 '24 | 667M | 326M | 342M | -716M | -847M | 2.900 |
| Q3 '24 | 650M | 294M | 356M | 653M | 923M | 2.010 |
Insider Transactions View All
| BARRY JAMES filed to sell 510 shares at $306.2. November 10 '25 |
| Crowley Michael filed to sell 8,171 shares at $247.1. March 18 '25 |
| Last Andrew J. filed to sell 7,559 shares at $329.9. September 10 '24 |
| BARRY JAMES filed to sell 147 shares at $330.5. September 4 '24 |
| Crowley Michael filed to sell 6,573 shares at $281.9. June 14 '24 |
Similar companies
Read more about Bio-Rad (BIO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Bio-Rad
The Market Cap of Bio-Rad is $7.09B.
As of today, Bio-Rad's PE (Price to Earnings) ratio is 9.43.
Currently, the price of one share of Bio-Rad stock is $262.80.
The BIO stock price chart above provides a comprehensive visual representation of Bio-Rad's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bio-Rad shares. Our platform offers an up-to-date BIO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Bio-Rad (BIO) does not offer dividends to its shareholders. Investors interested in Bio-Rad should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Bio-Rad are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
